Radiotheranostics Market Growth, Size, Trends Analysis - By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Radiotheranostics Market Introduction and Overview

According to SPER market research, 'Global Radiotheranostics Market Size- By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Radiotheranostics Market is predicted to reach 35.22 billion by 2034 with a CAGR of 13.74%.

Radiotheranostics is a new area in medicine that merges diagnosis and treatment using radiopharmaceuticals. It uses radiotracers, which are molecules with radioactive isotopes, to diagnose and treat diseases at the same time. Techniques like positron emission tomography (PET) or single-photon emission computed tomography (SPECT) are used to identify specific targets in the body, offering precise and personalized diagnosis by detailing the disease's location and extent. The treatment entails providing radiation therapy to the illness site.

Restraints: The high cost of radiopharmaceuticals and radiotheranostics treatments can cause problems for patients and healthcare professionals alike. The cost-effectiveness and affordability of these technologies need to be addressed in order to ensure further adoption and market expansion.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Radioisotope, By Approach, By Application

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA.

Global Radiotheranostics Market Segmentation:

By Radioisotope: Based on the Radioisotope, Global Radiotheranostics Market is segmented as; Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90.

By Approach: Based on the Approach, Global Radiotheranostics Market is segmented as; Targeted Therapeutic, Targeted Diagnostic.

By Application: Based on the Application, Global Radiotheranostics Market is segmented as; Oncology, Non-oncology.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25127

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Radiotheranostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Radiotheranostics Market

7. Global Radiotheranostics Market, By Radioisotope (USD Million) 2021-2034

7.1. Iodine-131
7.2. Iodine-123
7.3. Gallium-68
7.4. Lutetium-177
7.5. 18F with Y-90
7.6. Others

8. Global Radiotheranostics Market, By Approach (USD Million) 2021-2034

8.1. Targeted Therapeutic
8.2. Targeted Diagnostic

9. Global Radiotheranostics Market, By Application (USD Million) 2021-2034

9.1. Oncology
- 9.1.1. Thyroid Cancer
- 9.1.2. Neuroendocrine Tumor
- 9.1.3. Hepatocellular Carcinoma
- 9.1.4. Prostate Cancer
- 9.1.5. Others
9.2. Non-oncology
- 9.2.1. Neurological Disorders
- 9.2.2. Arthritis
- 9.2.3. Others

10. Global Radiotheranostics Market, (USD Million) 2021-2034

10.1. Global Radiotheranostics Market Size and Market Share

11. Global Radiotheranostics Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Novartis AG
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Bayer AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Progenics Pharmaceuticals, Inc.(Lantheus)
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Telix Pharmaceuticals Limited
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. ITM Radiopharma
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Life Molecular Imaging
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. RadioMedix
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. IsoTherapeutics Group, LLC
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Q BioMed Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Nordic Nanovector ASA
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others